Advanced Biotherapy Inc. Broadens Its Patent Estate.

Business Editors/Health & Medical Writers

LOS ANGELES--(BUSINESS WIRE)--March 18, 2003

Advanced Biotherapy Inc. (OTCBB:ADVB) was notified by the United States Patent and Trademark Office (USPTO) that it has been issued U.S. Patent No. 6,534,059 for the use of antibody to gamma interferon to treat corneal transplant rejection. The patent will not expire until June, 2021.

The Company's Chief Executive Officer, Mr. Edmond Buccellato, stated, "The issuance of this method of use patent continues to broaden our intellectual property protection as we successfully build our patent estate covering the Company's underlying technology. Our core science is focused -- the patented use of antibodies directed to a single target that are being developed as therapies for multiple diseases. This use patent will contribute to our strategy to partner with, or license our technology to, pharma or biotech companies engaged in treating a variety of diseases associated with hyperproduction of gamma interferon. As previously reported, we were issued a method of use patent for the exclusive use of antibodies to gamma interferon to treat rheumatoid arthritis (RA), juvenile RA, Psoriatic RA, Multiple Sclerosis and Ankylosing Spondylitis."

Mr. Buccellato also stated, "As noted in the June 2002 issue of the American Journal of Ophthalmology, our investigational antibodies to gamma interferon was used to treat thirteen patients who were experiencing corneal transplant rejection after corneal grafting. In all patients, transplant rejection was halted -- transparency improved, edema dropped, and visual acuity increased."

He further commented, "In a press release dated June 12, 2001, the USPTO stated its policy: '...that it administers patent and trademark laws protecting intellectual property and rewarding individual effort. Intellectual property is a potent force in the competitive free enterprise system. By protecting intellectual endeavors and encouraging technological progress, USPTO seeks to preserve the United States' technological edge, which is a key to our current and future competitiveness.' Advanced Biotherapy and its shareholders are, and will continue to be, the beneficiaries of that policy as we employ our efforts in the pursuit to develop our novel therapy to treat people who suffer from certain painful and debilitating autoimmune diseases."

Advanced Biotherapy is developing new therapeutic strategies for the treatment of severe autoimmune diseases by the use of biologic drugs that may be developed under the company's patents and patents pending to neutralize immunomodulators called cytokines, which have been linked to diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and a host of other autoimmune diseases.

Statements made in this news release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the anticipated results or other expectations expressed in our forward-looking statements. The risks and uncertainties which may affect the development, operations and results of our business include, but are not limited to the following: risks associated with clinical trials, the uncertainties of research and product development programs, the uncertainties of the regulatory approval process, the risks of competitive products, the risks of our current capital resources, the uncertainties as to the availability of future capital and our future capital requirements, and the risks associated with the extent and breadth of the Company's patent portfolio. The foregoing discussion of the effect of the patents issued and pending involves risks and uncertainties, including but not limited to the risks that third parties may be successful in challenging such patents; or that granted claims may be held invalid or interpreted differently by a court of law; or that new technologies will be developed that are superior in treating the diseases targeted by Advanced Biotherapy, Inc. Readers are cautioned not to place reliance on these forward-looking statements, which speak only as of the date the statements were made. See the Company's public filings with the Securities and Exchange Commission for further information about risks and uncertainties that may affect the Company and the results or expectations expressed in our forward-looking statements, including the section captioned "Factors That May Affect The Company" contained in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2001.